Slide 1: Job code CP-362887, January 2023
Job code: CP-362887 Date: January 2023 1
Slide 2: Overview
OVERVIEW 1. Why Janssen initiated the Freedom from Disease study 2. The current psoriasis landscape 3. The Delphi consensus method 4. Results from key stages of the Delphi consensus 5. Achievements and next steps 2
Slide 3: Why Janssen initiated the Freedom from Disease study
WHY JANSSEN INITIATED THE FREEDOM FROM DISEASE STUDY Why is this important to people with psoriasis? Janssen is a key advocate for people living with TREATMENT2,3 NEEDS2,3 psoriasis in Europe Changing the treatment paradigm will enable all people A better understanding of the needs of people with ps
Slide 4: The current psoriasis landscape
THE CURRENT PSORIASIS LANDSCAPE 4
Slide 5: Psoriasis is a chronic disease with high disease burden
PSORIASIS IS A CHRONIC DISEASE WITH HIGH DISEASE BURDEN AND AFFECTS PEOPLE IN SEVERAL WAYS1 Physical1–3 Social1,2,4 • Scaling • Friends and family • Itching • Education • Erythema • Professional career • Common comorbidities: • Arthritis Psychological2–4 • Cardiovascular diseases • Fatigue • Metabol
Slide 6: Underdiagnosed and undertreated psoriasis in important areas impacts QoL
UNDERDIAGNOSED AND UNDERTREATED PSORIASIS IN IMPORTANT AREAS CAN HAVE A DISPROPORTIONATE IMPACT ON QOL1 Scalp: Itching, bleeding, embarrassment, and choice Face: Highly visible, can result of clothing limited in impaired vision, hearing and chewing/swallowing • Psoriasis of the scalp, face, intertri
Slide 7: Patients and dermatologists assess psoriasis disease severity differently
PATIENTS AND DERMATOLOGISTS ASSESS PSORIASIS DISEASE SEVERITY DIFFERENTLY1 Top 5 most important factors contributing to disease severity Findings from the USA* 76.2% • Lesion location and size was most important 36.1% to dermatologists • However, itching was most important to 21.8% people living wit
Slide 8: Current outcome measures do not always capture patient needs
CURRENT OUTCOME MEASURES DO NOT ALWAYS CAPTURE THE NEEDS AND PRIORITIES OF PEOPLE WITH PSORIASIS1–3 Physician-reported outcomes Patient-reported outcomes Measure reduction in disease Measure subjective disease severity and lesion size severity alongside physical and mental well-being Example: Exampl
Slide 9: Treatment success by PASI and DLQI may not feel like success
Even after achieving treatment success according to PASI and DLQI, people with psoriasis may not feel that treatment success has been achieved Need to achieve consensus from people with psoriasis and HCPs on how to define the concept of freedom from disease 9 DLQI, Dermatology Life Quality Index; HC
Slide 10: Delphi studies generally do not give people with psoriasis a substantial voice
DELPHI STUDIES GENERALLY DO NOT GIVE PEOPLE WITH PSORIASIS A SUBSTANTIAL VOICE Study International Psoriasis Delphi consensus Belgian Delphi Delphi consensus on description Council Delphi consensus1 on defining drug- consensus on defining minimal disease activity4 free remission2 treat-to-target out
Slide 11: Consensus meetings can aid in assessing relevant aspects of disease
CONSENSUS MEETINGS CAN AID IN APPROPRIATELY ASSESSING RELEVANT ASPECTS OF DISEASE There is a current need to:2 • WHO global report on psoriasis highlighted the need for people-centred care1 • Go beyond traditional concepts of clinical remission and QoL measures • Current physician-reported and patie
Slide 12: The Delphi consensus method
THE DELPHI CONSENSUS METHOD 12
Slide 13: What is a Delphi consensus?
WHAT IS A DELPHI CONSESUS?1–3 The Delphi method is a well-established and reliable approach to gaining expert consensus on a topic1,3 Iterative process Anonymous survey A standardised, Participants review Feedback on results (with one or multiple of experts adaptable responses and with the opportuni
Slide 14: The modified Delphi consensus process
THE MODIFIED DELPHI CONSENSUS PROCESS1 Nonsystematic literature review • Undertaken to provide: • Evidence reflecting the views and priorities of people with psoriasis • Information on domains Literature review and Short online survey for people with pre-meeting questionnaire* psoriasis, nurses and
Slide 15: The modified Delphi consensus process
THE MODIFIED DELPHI CONSENSUS PROCESS1 Separate workshops were conducted to encourage individuals to speak more openly without worrying how other groups might interpret their opinions Literature review and Pre-workshop questionnaire Workshop questions included questions pre-meeting questionnaire* re
Slide 16: The modified Delphi consensus process
THE MODIFIED DELPHI CONSENSUS PROCESS1 Literature review and Pre-workshop questionnaire Voting round 1 The questionnaire was modified in pre-meeting questionnaire* response to the top five statements voted for in each domain during voting round 1 Facilitating Consensus • The wording of some of the t
Slide 17: Choosing a diverse and geographically heterogeneous panel
CHOOSING A DIVERSE AND GEOGRAPHICALLY Drive content HETEROGENEOUS PANEL of programme Facilitating Dermatologists and nurses consensus • Experience in psoriasis as assessed by: group • Publications • Citations Voting • Presentations consensus • Participation in guideline development panel People with
Slide 18: Results from key stages of the Delphi consensus
RESULTS FROM KEY STAGES OF THE DELPHI CONSENSUS 18
Slide 19: We received an unprecedented level of engagement
WE RECEIVED AN UNPRECEDENTED LEVEL OF ENGAGEMENT Voting group across Europe: responses received from 15 countries 21 dermatologists 21 dermatologists Round 1 Round 2 166 130 responses responses Belgium Netherlands Croatia Poland Denmark Portugal France Romania Germany Spain 11 nurses 13 nurses Hunga
Slide 20: Further characteristics
FURTHER CHARACTERISTICS Voting round 1 Disease severity (people with Gender (all responders; n=166) psoriasis; n=129) Age (all responders; n=166) 5.4% 0.8% 37.6% Mild 32.6% 36.7% 37.3% 27.1% Moderate <40 Female Male Severe ≥40 62.0% Preferred not to say 63.3% Other 34.1% Voting round 2 Disease sever
Slide 21: Key conclusions from the virtual planning meeting
KEY CONCLUSIONS FROM THE VIRTUAL PLANNING MEETING Literature review Facilitating Domain Pre-workshop and pre-meeting Consensus Panel identification questionnaire questionnaire planning meeting There is a paucity of Current clinical No single patient Facilitating Facilitating Draft Consensus Panel Co
Slide 22: Development of multi-dimensional domains
DEVELOPMENT OF MULTI-DIMENSIONAL DOMAINS WELL-BEING BEYOND SKIN Literature review Facilitating Domain Pre-workshop and pre-meeting Consensus Panel identification questionnaire questionnaire planning meeting • To be able to lead a normal everyday life • To have no fear that the disease will become wo
Slide 23: Key conclusions from the workshop with people with psoriasis
KEY CONCLUSIONS FROM THE WORKSHOP WITH PEOPLE WITH PSORIASIS The participants used the Literature review and pre-meeting Facilitating Domain Pre-workshop following language to describe Consensus Panel identification questionnaire questionnaire planning meeting freedom from disease: Facilitating Faci
Slide 24: Key conclusions from the workshop with nurses and dermatologists
KEY CONCLUSIONS FROM THE WORKSHOP WITH NURSES AND DERMATOLOGISTS Literature review Facilitating Domain Pre-workshop Nurses Dermatologists need to: and pre-meeting Consensus Panel identification questionnaire questionnaire planning meeting • The communication with the patient is vital • Empower peopl
Slide 25: Results from Round 1
Treatment RESULTS FROM ROUND 1* My treatment helps me feel in control of my disease I have access to all treatments that I need to manage my symptoms 70 70 My treatment has a long-lasting effect 68 I have broken the cycle of hope and disappointment 66 Literature review Facilitating Domain Pre-worksh
Slide 26: Results from Round 2
RESULTS FROM ROUND 2* Treatment I have access to all treatments that I need to manage my symptoms 70 My treatment has a long-lasting effect 60 My treatment helps me feel in control of my disease 53 I understand my psoriasis and know what treatments are available 41 I do not worry about the side effe
Slide 27: Consensus statement
CONSENSUS STATEMENT Literature review Facilitating Domain Pre-workshop and pre-meeting Consensus Panel identification questionnaire questionnaire planning meeting Facilitating Facilitating Draft Consensus Voting Consensus Panel workshops Panel drafted statements round 1 Freedom from disease is multi
Slide 28: Consensus statement
CONSENSUS STATEMENT 1. QoL and well-being For individuals, control of psoriasis means that their daily routine at home and at work, their relationships and social life, and intimacy are all returned to normal. This enables them to live confidently, without psoriasis impacting their life. 2. Healthca
Slide 29: Achievements and next steps
ACHIEVEMENTS AND NEXT STEPS 29 FREEDOM FROM DISEASE IN PSORIASIS
Slide 30: Freedom from disease requires the needs of all five domains to be addressed
FREEDOM FROM DISEASE REQUIRES THE NEEDS OF ALL FIVE DOMAINS TO BE SUFFICIENTLY ADDRESSED QoL and well-being • Having control of their disease • Improving care and treatment of comorbidities* Psychosocial Management of clinical • Not being defined by symptoms their psoriasis • Clear from visible lesi
Slide 31: The modified Delphi methodology provided a broad and precise consensus
THE MODIFIED DELPHI METHODOLOGY USED PROVIDED A BROAD AND PRECISE CONSENSUS • Largest Delphi consensus to include people with psoriasis at every stage of the process • Providing an accurate consensus across those with psoriasis and those involved in treatment The consensus achieved for Freedom from
Slide 32: To conclude: achievements and next steps
TO CONCLUDE: ACHIEVEMENTS AND NEXT STEPS Largest Delphi consensus to fully incorporate the views of people with psoriasis at the time of its publication (January 2022) Final consensus statements provide new insight into the concept of freedom from disease Europe-wide response, with input from people
Slide 33: Janssen aims to increase awareness of the needs of people with psoriasis
Janssen aims to increase awareness of the needs of people with psoriasis This will be achieved by continuing their engagement within the psoriasis field, providing publication strategy support and progressing panel insights gained 33
Slide 34: Thank you
THANK YOU FREED © hd FROM DISEASE IN PSORIASIS